William Freund, MD
Interventional Cardiology · Manhattan, KSNPI 1710942685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 44 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$206
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$193
- Merck$163
- Abiomed$97
- Esperion Therapeutics, Inc.$83
- Shockwave Medical, Inc$45
- plus $160 from 6 others
What the payments were for
- Food & beverage$947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $206 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $193 |
| Merck | 10 | $163 |
| Abiomed | 3 | $97 |
| Esperion Therapeutics, Inc. | 1 | $83 |
| Shockwave Medical, Inc | 2 | $45 |
| Siemens Medical Solutions USA, Inc. | 1 | $41 |
| Johnson & Johnson | 3 | $40 |
| Terumo Medical Corporation | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Amgen | 1 | $18 |
| Philips North America LLC | 1 | $14 |
How this compares
$947 in reported general payments places this provider in the 5th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 189 | $125,185 |
| EliquisApixaban | 142 | $97,438 |
| EntrestoSacubitril/Valsartan | 21 | $20,289 |
| FarxigaDapagliflozin Propanediol | 13 | $7,247 |
| Ranolazine ErRanolazine | 15 | $3,096 |
| Pravastatin Sodium | 126 | $2,848 |
| ZypitamagPitavastatin Magnesium | 12 | $2,657 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $2,261 |
| Metoprolol Succinate | 205 | $2,188 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 147 | $1,716 |
| Losartan Potassium | 151 | $1,250 |
| Potassium Chloride | 56 | $1,184 |
| Digoxin | 56 | $1,163 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 63 | $1,103 |
| Amiodarone Hcl | 131 | $1,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $40 | $125,185189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Manhattan
- Priyantha RanaweeraManhattan$41K
- Ramez SmairatManhattan$11K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
- John SerfasKansas City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.